Listed

Exozymes Inc.

EXOZNasdaqCIK 2010788HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue−$700, period not labelled
Operating income−$3.0m, Q2 FY2026
Net income−$2.9m, Q2 FY2026
Exozymes Inc., income statement, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31period not labelled2024-03-31period not labelled2024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$knot reported(0.7)Revenue, period not labelled, three months to 2023-12-31−$700. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001641172-25-001744. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k27.9Research and development, period not labelled, three months to 2023-09-30$27.9k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure460Research and development, period not labelled, three months to 2023-12-31$460.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001641172-25-001744. Derived: 12-month figure less the 9-month figure.Report this figure278Research and development, period not labelled, three months to 2024-03-31$277.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure237Research and development, period not labelled, three months to 2024-06-30$237.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure723Research and development, Q3 FY2024, three months to 2024-09-30$723.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure630Research and development, Q4 FY2024, three months to 2024-12-31$630.3k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure575Research and development, Q1 FY2025, three months to 2025-03-31$575.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure803Research and development, Q2 FY2025, three months to 2025-06-30$803.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure1,217Research and development, Q3 FY2025, three months to 2025-09-30$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure1,112Research and development, Q4 FY2025, three months to 2025-12-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure1,121Research and development, Q1 FY2026, three months to 2026-03-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure1,438Research and development, Q2 FY2026, three months to 2026-06-30$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Operating income$k(392)Operating income, period not labelled, three months to 2023-09-30−$391.8k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure(985)Operating income, period not labelled, three months to 2023-12-31−$985.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001641172-25-001744. Derived: 12-month figure less the 9-month figure.Report this figure(1,008)Operating income, period not labelled, three months to 2024-03-31−$1.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure(1,329)Operating income, period not labelled, three months to 2024-06-30−$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure(1,612)Operating income, Q3 FY2024, three months to 2024-09-30−$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure(1,983)Operating income, Q4 FY2024, three months to 2024-12-31−$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure(1,951)Operating income, Q1 FY2025, three months to 2025-03-31−$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(2,548)Operating income, Q2 FY2025, three months to 2025-06-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure(2,522)Operating income, Q3 FY2025, three months to 2025-09-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure(2,695)Operating income, Q4 FY2025, three months to 2025-12-31−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure(2,387)Operating income, Q1 FY2026, three months to 2026-03-31−$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(2,954)Operating income, Q2 FY2026, three months to 2026-06-30−$3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Interest expense$knot reportednot reportednot reportednot reported44.6Interest expense, Q3 FY2024, three months to 2024-09-30$44.6k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$knot reportednot reportednot reported2.1Income tax, period not labelled, three months to 2024-06-30$2.1k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure(0.0)Income tax, Q3 FY2024, three months to 2024-09-30−$1. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001493152-25-022289. Derived: 9-month figure less the 6-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(521)Net income, period not labelled, three months to 2023-09-30−$520.6k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure(1,099)Net income, period not labelled, three months to 2023-12-31−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001641172-25-001744. Derived: 12-month figure less the 9-month figure.Report this figure(1,008)Net income, period not labelled, three months to 2024-03-31−$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure(1,361)Net income, period not labelled, three months to 2024-06-30−$1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure(1,656)Net income, Q3 FY2024, three months to 2024-09-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure(1,836)Net income, Q4 FY2024, three months to 2024-12-31−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure(1,856)Net income, Q1 FY2025, three months to 2025-03-31−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure(2,360)Net income, Q2 FY2025, three months to 2025-06-30−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure(2,287)Net income, Q3 FY2025, three months to 2025-09-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure(2,655)Net income, Q4 FY2025, three months to 2025-12-31−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure(2,370)Net income, Q1 FY2026, three months to 2026-03-31−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure(2,879)Net income, Q2 FY2026, three months to 2026-06-30−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Diluted EPS$ per share(0.08)Diluted EPS, period not labelled, three months to 2023-09-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figurenot reported(0.16)Diluted EPS, period not labelled, three months to 2024-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure(0.22)Diluted EPS, period not labelled, three months to 2024-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure(0.27)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figurenot reported(0.22)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(0.28)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure(0.27)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figurenot reported(0.28)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(0.33)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Basic EPS$ per share(0.08)Basic EPS, period not labelled, three months to 2023-09-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figurenot reported(0.16)Basic EPS, period not labelled, three months to 2024-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure(0.22)Basic EPS, period not labelled, three months to 2024-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure(0.27)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figurenot reported(0.22)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(0.28)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure(0.27)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figurenot reported(0.28)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(0.33)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure

Balance sheet

Cash and equivalents$5.7m, Q2 FY2026
Shareholders' equity$3.7m, Q2 FY2026
Exozymes Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31period not labelled2024-03-31period not labelled2024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reported0.1Cash and equivalents, period not labelled, at 2023-12-31$66.5k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001641172-25-001744.Report this figurenot reportednot reported0.2Cash and equivalents, Q3 FY2024, at 2024-09-30$233.9k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure9.7Cash and equivalents, FY2024, at 2024-12-31$9.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001493152-26-013563.Report this figure8.5Cash and equivalents, Q1 FY2025, at 2025-03-31$8.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure7.0Cash and equivalents, Q2 FY2025, at 2025-06-30$7.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure5.1Cash and equivalents, Q3 FY2025, at 2025-09-30$5.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure3.0Cash and equivalents, FY2025, at 2025-12-31$3.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure1.4Cash and equivalents, Q1 FY2026, at 2026-03-31$1.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure5.7Cash and equivalents, Q2 FY2026, at 2026-06-30$5.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Current assets$mnot reported1.2Current assets, period not labelled, at 2023-12-31$1.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001641172-25-001744.Report this figurenot reportednot reported1.4Current assets, Q3 FY2024, at 2024-09-30$1.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure10.8Current assets, FY2024, at 2024-12-31$10.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001493152-26-013563.Report this figure9.4Current assets, Q1 FY2025, at 2025-03-31$9.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure7.5Current assets, Q2 FY2025, at 2025-06-30$7.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure5.6Current assets, Q3 FY2025, at 2025-09-30$5.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure3.9Current assets, FY2025, at 2025-12-31$3.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure2.1Current assets, Q1 FY2026, at 2026-03-31$2.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure6.2Current assets, Q2 FY2026, at 2026-06-30$6.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Total assets$mnot reported3.6Total assets, period not labelled, at 2023-12-31$3.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001641172-25-001744.Report this figurenot reportednot reported3.6Total assets, Q3 FY2024, at 2024-09-30$3.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure13.0Total assets, FY2024, at 2024-12-31$13.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001493152-26-013563.Report this figure11.5Total assets, Q1 FY2025, at 2025-03-31$11.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure9.7Total assets, Q2 FY2025, at 2025-06-30$9.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure7.7Total assets, Q3 FY2025, at 2025-09-30$7.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure6.0Total assets, FY2025, at 2025-12-31$6.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure4.0Total assets, Q1 FY2026, at 2026-03-31$4.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure8.0Total assets, Q2 FY2026, at 2026-06-30$8.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Current liabilities$mnot reported2.4Current liabilities, period not labelled, at 2023-12-31$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001641172-25-001744.Report this figurenot reportednot reported5.8Current liabilities, Q3 FY2024, at 2024-09-30$5.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure1.3Current liabilities, FY2024, at 2024-12-31$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001493152-26-013563.Report this figure1.4Current liabilities, Q1 FY2025, at 2025-03-31$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure1.2Current liabilities, Q2 FY2025, at 2025-06-30$1.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure1.2Current liabilities, Q3 FY2025, at 2025-09-30$1.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure1.6Current liabilities, FY2025, at 2025-12-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure1.6Current liabilities, Q1 FY2026, at 2026-03-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure1.6Current liabilities, Q2 FY2026, at 2026-06-30$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Total liabilities$mnot reported3.9Total liabilities, period not labelled, at 2023-12-31$3.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001641172-25-001744.Report this figurenot reportednot reported7.2Total liabilities, Q3 FY2024, at 2024-09-30$7.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure2.6Total liabilities, FY2024, at 2024-12-31$2.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001493152-26-013563.Report this figure2.6Total liabilities, Q1 FY2025, at 2025-03-31$2.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure2.4Total liabilities, Q2 FY2025, at 2025-06-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure2.3Total liabilities, Q3 FY2025, at 2025-09-30$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure2.6Total liabilities, FY2025, at 2025-12-31$2.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure2.5Total liabilities, Q1 FY2026, at 2026-03-31$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure4.3Total liabilities, Q2 FY2026, at 2026-06-30$4.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure
Shareholders' equity$m0.6Shareholders' equity, period not labelled, at 2023-09-30$607.1k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure(0.4)Shareholders' equity, period not labelled, at 2023-12-31−$384.3k. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001493152-26-013563.Report this figure(1.2)Shareholders' equity, period not labelled, at 2024-03-31−$1.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure(2.3)Shareholders' equity, period not labelled, at 2024-06-30−$2.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure(3.6)Shareholders' equity, Q3 FY2024, at 2024-09-30−$3.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure10.4Shareholders' equity, FY2024, at 2024-12-31$10.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure8.9Shareholders' equity, Q1 FY2025, at 2025-03-31$8.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure7.2Shareholders' equity, Q2 FY2025, at 2025-06-30$7.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure5.4Shareholders' equity, Q3 FY2025, at 2025-09-30$5.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure3.4Shareholders' equity, FY2025, at 2025-12-31$3.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure1.5Shareholders' equity, Q1 FY2026, at 2026-03-31$1.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure3.7Shareholders' equity, Q2 FY2026, at 2026-06-30$3.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure

Cash flow

Operating cash flow−$1.6m, Q2 FY2026
Capital expenditure−$1, Q2 FY2026
Exozymes Inc., cash flow, quarterly
Line itemUnitperiod not labelled2023-12-31period not labelled2024-03-31period not labelled2024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(783)Operating cash flow, period not labelled, three months to 2023-12-31−$783.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001641172-25-001744. Derived: 12-month figure less the 9-month figure.Report this figure281Operating cash flow, period not labelled, three months to 2024-03-31$281.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure(2,538)Operating cash flow, period not labelled, three months to 2024-06-30−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001641172-25-023184. Derived: 6-month figure less the 3-month figure.Report this figure(542)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$541.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001493152-25-022289. Derived: 9-month figure less the 6-month figure.Report this figure(5,708)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure(1,134)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(1,538)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037725. Derived: 6-month figure less the 3-month figure.Report this figure(1,857)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001493152-25-022289. Derived: 9-month figure less the 6-month figure.Report this figure(1,974)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure(1,524)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(1,640)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037725. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k110Capital expenditure, period not labelled, three months to 2023-12-31$109.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001641172-25-001744. Derived: 12-month figure less the 9-month figure.Report this figure149Capital expenditure, period not labelled, three months to 2024-03-31$148.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure37.2Capital expenditure, period not labelled, three months to 2024-06-30$37.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0001641172-25-023184. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001493152-25-022289. Derived: 9-month figure less the 6-month figure.Report this figure210Capital expenditure, Q4 FY2024, three months to 2024-12-31$210.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure31.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$31.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure50.6Capital expenditure, Q2 FY2025, three months to 2025-06-30$50.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001493152-26-037725. Derived: 6-month figure less the 3-month figure.Report this figure13.3Capital expenditure, Q3 FY2025, three months to 2025-09-30$13.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001493152-25-022289. Derived: 9-month figure less the 6-month figure.Report this figure75.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$75.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001493152-26-013563. Derived: 12-month figure less the 9-month figure.Report this figure57.6Capital expenditure, Q1 FY2026, three months to 2026-03-31$57.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure(0.0)Capital expenditure, Q2 FY2026, three months to 2026-06-30−$1. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001493152-26-037725. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)8.66m, Q2 FY2026
Exozymes Inc., shares, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2024-03-31period not labelled2024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)k shares6,250Diluted shares (weighted), period not labelled, three months to 2023-09-306,250,002 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001493152-24-044813.Report this figure6,250Diluted shares (weighted), period not labelled, three months to 2024-03-316,250,002 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001641172-25-009636.Report this figure6,251Diluted shares (weighted), period not labelled, three months to 2024-06-306,251,111 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0001641172-25-023184.Report this figure6,252Diluted shares (weighted), Q3 FY2024, three months to 2024-09-306,252,349 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure8,368Diluted shares (weighted), Q1 FY2025, three months to 2025-03-318,367,810 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure8,377Diluted shares (weighted), Q2 FY2025, three months to 2025-06-308,377,265 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure8,387Diluted shares (weighted), Q3 FY2025, three months to 2025-09-308,387,250 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001493152-25-022289.Report this figure8,459Diluted shares (weighted), Q1 FY2026, three months to 2026-03-318,458,847 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001493152-26-023035.Report this figure8,660Diluted shares (weighted), Q2 FY2026, three months to 2026-06-308,660,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure

Shares outstanding: 9.28mShares outstanding, period not labelled, at 2026-08-139,281,359 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037725.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.